Aimmune shareholders accept $2 billion Nestle tender offer

By Sam Nussey Posted on October 13, 2020

Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics

ZURICH (Reuters) – Aimmune Therapeutics Inc <AIMT.O> shareholders have backed Nestle’s <NESN.S> $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer’s expiration date. “The minimum tender condition to the consummation of the offer set forth in the offer to purchase has been satisfied,” Nestle said.

(Reporting by Michael Shields, editing by Kirsti Knolle)